PMFA
SUPN icon

Plante Moran Financial Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Plante Moran Financial Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,066
Closed -$26K – 1033
2016
Q3 		$26K Buy
+1,066
New +$24.1K 0.02% 435
2016
Q1 		– Sell
-67
Closed -$1K – 1018
2015
Q4 		$1K Buy
+67
New +$1.04K ﹤0.01% 917

Other funds holding SUPN

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Plante Moran Financial Advisors's SUPN Position: Q4 2016 in Review

Plante Moran Financial Advisors sold out of Supernus Pharmaceuticals (SUPN) in Q4 2016, closing a stake of 1,066 shares — an estimated $26K sold.

Plante Moran Financial Advisors first reported a position in SUPN in Q4 2015 and held it in 2 quarters. The position peaked at $26K in Q3 2016. 233 funds tracked by Wall St. Rank hold SUPN as of Q4 2016.

  • Plante Moran Financial Advisors reported no remaining Supernus Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Plante Moran Financial Advisors sold 1,066 Supernus Pharmaceuticals shares in Q4 2016, an estimated $26K.
  • Plante Moran Financial Advisors first reported a position in Supernus Pharmaceuticals in Q4 2015 and held it in 2 quarters.
  • Plante Moran Financial Advisors's Supernus Pharmaceuticals position peaked at $26K in Q3 2016.
  • 233 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2016.

Based on Plante Moran Financial Advisors's 13F filing for Q4 2016, filed 27 Jan 2017.